Capsular switching as a strategy to increase pneumococcal virulence in experimental otitis media model

Microbes and Infection

Volumn 16, Issue 4, 2014, Pages 292-299

  Sabharwal, Vishakha ^a   Stevenson, Abbie ^b   Figueira, Marisol ^a   Orthopoulos, George ^a   Trzciński, Krzysztof ^c   Pelton, Stephen I ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Capsular switching; Pneumococcal; Virulence

Indexed keywords

COMPLEMENT COMPONENT C3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; CAPSULAR SWITCHING; CHINCHILLA; CONTROLLED STUDY; NONHUMAN; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; ANIMAL; BACTERIAL CAPSULE; CHEMISTRY; DISEASE MODEL; GENETIC RECOMBINATION; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; PATHOLOGY; STREPTOCOCCUS PNEUMONIAE; VIRULENCE;

ANIMALIA; CHINCHILLIDAE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; BACTERIAL CAPSULES; CHINCHILLA; COMPLEMENT C3; DISEASE MODELS, ANIMAL; HUMANS; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; RECOMBINATION, GENETIC; STREPTOCOCCUS PNEUMONIAE; VIRULENCE;

EID: 84899487428     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2013.12.002     Document Type: Article

References (50)

1. Kaplan S.L., Mason E.O., Wald E.R., Schutze G.E., Bradley J.S., Tan T.Q., et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004, 113:443-449.
2. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Finnish otitis media study G, efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
3. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
4. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
5. Weinberger D.M., Harboe Z.B., Flasche S., Scott J.A., Lipsitch M. Prediction of serotypes causing invasive pneumococcal disease in unvaccinated and vaccinated populations. Epidemiology 2011, 22:199-207.
6. Huang S.S., Hinrichsen V.L., Stevenson A.E., Rifas-Shiman S.L., Kleinman K., Pelton S.I., et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics 2009, 124:e1-11.
7. Russell F.M., Carapetis J.R., Satzke C., Tikoduadua L., Waqatakirewa L., Chandra R., et al. Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster. Clin Vaccine Immunol 2010, 17:1970-1976.
8. Huang S.S., Platt R., Rifas-Shiman S.L., Pelton S.I., Goldmann D., Finkelstein J.A. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005, 116:e408-e413.
9. Brueggemann A.B., Peto T.E., Crook D.W., Butler J.C., Kristinsson K.G., Spratt B.G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190:1203-1211.
10. Yildirim I., Hanage W.P., Lipsitch M., Shea K.M., Stevenson A., Finkelstein J., et al. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29:283-288.
11. Temime L., Boelle P.Y., Opatowski L., Guillemot D. Impact of capsular switch on invasive pneumococcal disease incidence in a vaccinated population. PLoS One 2008, 3:e3244.
12. Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A 1997, 94:6571-6576.
13. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. J Am Med Assoc 2007, 297:1784-1792.
14. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
15. Golubchik T., Brueggemann A.B., Street T., Gertz R.E., Spencer C.C., Ho T., et al. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event. Nat Genet 2012, 44:352-355.
16. Coffey T.J., Enright M.C., Daniels M., Morona J.K., Morona R., Hryniewicz W., et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 1998, 27:73-83.
17. Marks L.R., Reddinger R.M., Hakansson A.P. High levels of genetic recombination during nasopharyngeal carriage and biofilm formation in Streptococcus pneumoniae. MBio 2012, 3.
18. Barnes D.M., Whittier S., Gilligan P.H., Soares S., Tomasz A., Henderson F.W. Transmission of multidrug-resistant serotype 23F Streptococcus pneumoniae in group day care: evidence suggesting capsular transformation of the resistant strain invivo. J Infect Dis 1995, 171:890-896.
19. Croucher N.J., Harris S.R., Fraser C., Quail M.A., Burton J., van der Linden M., et al. Rapid pneumococcal evolution in response to clinical interventions. Science 2011, 331:430-434.
20. Wyres K.L., Lambertsen L.M., Croucher N.J., McGee L., von Gottberg A., Linares J., et al. Pneumococcal capsular switching: a historical perspective. J Infect Dis 2013, 207:439-449.
21. Beall B., McEllistrem M.C., Gertz R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006, 44:999-1017.
22. Hiller N.L., Ahmed A., Powell E., Martin D.P., Eutsey R., Earl J., et al. Generation of genic diversity among Streptococcus pneumoniae strains via horizontal gene transfer during a chronic polyclonal pediatric infection. PLoS Pathog 2010, 6:e1001108.
23. Thomas J.C., Kong Y., Sabharwal V., Pelton S.I., Pettigrew M.M. Streptococcus pneumoniae serotype 6C: an intra- and interclonal complex comparison. J Bacteriol 2011, 193:3409-3410.
24. Nahm M.H., Lin J., Finkelstein J.A., Pelton S.I. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis 2009, 199:320-325.
25. Casey J.R., Adlowitz D.G., Pichichero M.E. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010, 29:304-309.
26. Millar E.V., Pimenta F.C., Roundtree A., Jackson D., Carvalho Mda G., Perilla M.J., et al. Pre- and post-conjugate vaccine epidemiology of pneumococcal serotype 6C invasive disease and carriage within Navajo and White Mountain Apache communities. Clin Infect Dis 2010, 51:1258-1265.
27. Park I.H., Moore M.R., Treanor J.J., Pelton S.I., Pilishvili T., Beall B., et al. Active bacterial core surveillance T, differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008, 198:1818-1822.
28. Sabharwal V., Ram S., Figueira M., Park I.H., Pelton S.I. Role of complement in host defense against pneumococcal otitis media. Infect Immun 2009, 77:1121-1127.
29. Sabharwal V., Figueira M., Pelton S.I., Pettigrew M.M. Virulence of Streptococcus pneumoniae serotype 6C in experimental otitis media. Microbes Infect 2012, 14:712-718.
30. Park I.H., Park S., Hollingshead S.K., Nahm M.H. Genetic basis for the new pneumococcal serotype, 6C. Infect Immun 2007, 75:4482-4489.
31. Casey J.R., Pichichero M.E. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004, 23:824-828.
32. Figueira M.A., Ram S., Goldstein R., Hood D.W., Moxon E.R., Pelton S.I. Role of complement in defense of the middle ear revealed by restoring the virulence of nontypeable Haemophilus influenzae siaB mutants. Infect Immun 2007, 75:325-333.
33. Babl F.E., Pelton S.I., Li Z. Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo. Antimicrob Agents Chemother 2002, 46:2194-2199.
34. Sung C.K., Li H., Claverys J.P., Morrison D.A. An rpsL cassette, janus, for gene replacement through negative selection in Streptococcus pneumoniae. Appl Environ Microbiol 2001, 67:5190-5196.
35. Trzcinski K., Thompson C.M., Lipsitch M. Construction of otherwise isogenic serotype 6B, 7F, 14, and 19F capsular variants of Streptococcus pneumoniae strain TIGR4. Appl Environ Microbiol 2003, 69:7364-7370.
36. Thomas J.C., Pettigrew M.M. Multilocus sequence typing and pulsed field gel electrophoresis of otitis media causing pathogens. Methods Mol Biol 2009, 493:179-190.
37. Yu J., Carvalho Mda G., Beall B., Nahm M.H. A rapid pneumococcal serotyping system based on monoclonal antibodies and PCR. J Med Microbiol 2008, 57:171-178.
38. Melin M., Jarva H., Siira L., Meri S., Kayhty H., Vakevainen M. Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun 2009, 77:676-684.
39. Kim J.O., Romero-Steiner S., Sorensen U.B., Blom J., Carvalho M., Barnard S., et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999, 67:2327-2333.
40. Brown E.J., Hosea S.W., Hammer C.H., Burch C.G., Frank M.M. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest 1982, 69:85-98.
41. Winkelstein J.A., Abramovitz A.S., Tomasz A. Activation of C3 via the alternative complement pathway results in fixation of C3b to the pneumococcal cell wall. J Immunol 1980, 124:2502-2506.
42. Hyams C., Trzcinski K., Camberlein E., Weinberger D.M., Chimalapati S., Noursadeghi M., et al. Streptococcus pneumoniae capsular serotype invasiveness correlates with the degree of factor H binding and opsonisation with C3b/iC3b. Infect Immun 2013, 81:354-363.
43. Duthy T.G., Ormsby R.J., Giannakis E., Ogunniyi A.D., Stroeher U.H., Paton J.C., et al. The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun 2002, 70:5604-5611.
44. Janulczyk R., Iannelli F., Sjoholm A.G., Pozzi G., Bjorck L. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 2000, 275:37257-37263.
45. Quin L.R., Carmicle S., Dave S., Pangburn M.K., Evenhuis J.P., McDaniel L.S. Invivo binding of complement regulator factor H by Streptococcus pneumoniae. J Infect Dis 2005, 192:1996-2003.
46. Zhang Y., Masi A.W., Barniak V., Mountzouros K., Hostetter M.K., Green B.A. Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 2001, 69:3827-3836.
47. Ren B., Szalai A.J., Hollingshead S.K., Briles D.E. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 2004, 72:114-122.
48. Tu A.H., Fulgham R.L., McCrory M.A., Briles D.E., Szalai A.J. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999, 67:4720-4724.
49. Hyams C., Yuste J., Bax K., Camberlein E., Weiser J.N., Brown J.S. Streptococcus pneumoniae resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun 2010, 78:716-725.
50. Sanchez C.J., Hinojosa C.A., Shivshankar P., Hyams C., Camberlein E., Brown J.S., et al. Changes in capsular serotype alter the surface exposure of pneumococcal adhesins and impact virulence. PLoS One 2011, 6:e26587.